



**VIJAYA**®  
**DIAGNOSTIC**  
**CENTRE**

**February 13, 2026**

To  
The Listing Department,  
**National Stock Exchange of India Limited**  
NSE Symbol: **VIJAYA**

To  
The Corporate Relations Department,  
**BSE Limited**  
BSE Scrip Code: **543350**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held on Friday, February 13, 2026 - Unaudited Financial Results for the quarter and nine months ended December 31, 2025**

**Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") as amended from time to time.**

We hereby inform you that, the Board of Directors at their meeting held today i.e., on **Friday, February 13, 2026**, has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2025.

In terms of the above, we enclose herewith the following:

- a. Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2025; and
- b. Limited review Reports on the Standalone & Consolidated Financial Results for the third quarter and nine months ended December 31, 2025.

The Board Meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).

Kindly take the same on record.

Thanking You.

Yours Faithfully  
For **Vijaya Diagnostic Centre Limited**

**Hansraj Singh**  
**Company Secretary & Compliance Officer**  
**M. No. F11438**

Encl.: As above



**VIJAYA  
DIAGNOSTIC  
CENTRE**

Vijaya Diagnostic Centre Limited  
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 31 December 2025

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited (Refer Note 5)	Unaudited (Refer Note 5)	Unaudited	Unaudited (Refer Note 5)	Audited (Refer Note 5)
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	19,308.31	18,935.33	15,770.93	55,916.17	47,236.45	63,400.30
	(b) Other income	554.51	515.21	481.21	1,793.06	1,303.18	1,852.09
	<b>Total income</b>	<b>19,862.82</b>	<b>19,450.54</b>	<b>16,252.14</b>	<b>57,709.23</b>	<b>48,539.63</b>	<b>65,252.39</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	2,291.98	2,263.79	1,980.03	6,571.63	5,858.50	7,923.24
	(b) Employee benefits expense	3,065.11	2,994.13	2,656.24	9,001.79	7,757.33	10,383.38
	(c) Finance costs	795.23	721.18	627.30	2,207.43	1,839.20	2,499.24
	(d) Depreciation and amortisation expense	2,124.75	1,939.68	1,689.37	5,900.57	4,751.67	6,466.43
	(e) Other expenses	5,682.97	5,826.49	4,840.34	17,214.92	14,633.92	19,624.71
	<b>Total expenses</b>	<b>13,960.04</b>	<b>13,745.27</b>	<b>11,793.28</b>	<b>40,896.34</b>	<b>34,840.62</b>	<b>46,897.00</b>
<b>3</b>	<b>Profit before tax and exceptional items [1-2]</b>	<b>5,902.78</b>	<b>5,705.27</b>	<b>4,458.86</b>	<b>16,812.89</b>	<b>13,699.01</b>	<b>18,355.39</b>
<b>4</b>	<b>Exceptional items (Refer Note 7)</b>	-	-	-	-	-	102.96
<b>5</b>	<b>Profit before tax [3-4]</b>	<b>5,902.78</b>	<b>5,705.27</b>	<b>4,458.86</b>	<b>16,812.89</b>	<b>13,699.01</b>	<b>18,252.43</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	1,155.00	1,243.90	867.32	3,542.00	2,952.33	3,892.56
	(b) Deferred tax	326.54	191.29	218.58	705.00	496.20	766.90
	<b>Total tax expense</b>	<b>1,481.54</b>	<b>1,435.19</b>	<b>1,085.90</b>	<b>4,247.00</b>	<b>3,448.53</b>	<b>4,659.46</b>
<b>7</b>	<b>Profit for the period/year [5 - 6]</b>	<b>4,421.24</b>	<b>4,270.08</b>	<b>3,372.96</b>	<b>12,565.89</b>	<b>10,250.48</b>	<b>13,592.97</b>
<b>8</b>	<b>Other comprehensive income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement of defined benefit liability / (asset)	(3.64)	39.50	(3.72)	26.28	(12.86)	(34.84)
	(b) Income-tax relating to above item	0.92	(9.94)	0.94	(6.61)	3.24	8.77
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>(2.72)</b>	<b>29.56</b>	<b>(2.78)</b>	<b>19.67</b>	<b>(9.62)</b>	<b>(26.07)</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7 + 8]</b>	<b>4,418.52</b>	<b>4,299.64</b>	<b>3,370.18</b>	<b>12,585.56</b>	<b>10,240.86</b>	<b>13,566.90</b>
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 4)</b>	1,027.25	1,027.25	1,026.29	1,027.25	1,026.29	1,026.37
<b>11</b>	<b>Other equity</b>						76,987.33
<b>12</b>	<b>Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	4.30	4.15	3.28	12.22	9.98	13.23
	- Diluted (in Rs.)	4.29	4.14	3.27	12.20	9.96	13.20

**Notes:**

1. The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 13 February 2026. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 31 December 2025. An unmodified report has been issued by them thereon.

3. The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".

4. During the quarter and year-to-date ended 31 December 2025, the Company has issued Nil and 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.

5. The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") of its subsidiary, Medinova Diagnostic Services Limited ("Transferor Company"), with the Company with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder.

The Scheme was sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies.

Accordingly, the Company has accounted for the amalgamation as specified in the Scheme in accordance with the "pooling of interest" method as laid down in Appendix C- 'Business Combinations of Entities Under Common Control' of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year.

In giving effect to the amalgamation:

a. All the assets, liabilities, reserves and surplus as appearing in the transferor company have been transferred and vested in the Company.

b. In consideration for the above Scheme, the Company will issue 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company. The shares of the Company to be issued to the non-controlling shareholders of the transferor company, on the record date, have been presented under 'Other Equity' as 'Shares pending issuance'.

c. The difference between value of share capital of transferor company and existing investment in the transferor company plus the Shares pending issuance as mentioned above has been transferred to 'Amalgamation Reserve' under 'Other Equity'.

Further to the above, the Company, on 8 January 2026, allotted 171,792 equity shares of INR 1 each in exchange for 3,779,420 equity shares held by the non-controlling shareholders of the transferor company. The Company has received in-principle listing approvals from the respective stock exchanges for the listing of 171,792 equity shares and in the process of executing the corporate action with the depositories.

6. The Government of India has consolidated existing labour legislations into four comprehensive labour codes effective November 21, 2025. These codes include Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). However, the final rules under these codes are yet to be notified.

Pending notification, the Company has evaluated the incremental impact of these changes in accordance with the guidance issued by the Institute of Chartered Accountants of India and has estimated and recognized the additional gratuity and leave liability basis the actuarial valuation. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

7. During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.

8. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of  
Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY  
Date: 2026.02.13  
13:58:02 +05'30'

S Suprita Reddy  
Managing Director & CEO  
DIN Number: 00263618

## Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Company has accounted for the amalgamation of Medinova Diagnostic Services Limited (“transferor company”) with the Company during the quarter and half year ended 30 September 2025 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025. The amalgamation has been accounted for by the Company by restating the financial information in the financial results in respect of the prior periods as if it had occurred from the beginning of the preceding year in the financial statements as per the requirement of Indian Accounting Standard.

The corresponding figures for the year ended 31 March 2025, in so far it pertains to the transferor company, have been audited by another auditor who had expressed an unmodified opinion on 3 May 2025.

Similarly, the corresponding figures for the quarter ended 30 September 2025 and the quarter and nine months ended 31 December 2024, in so far it pertains to the transferor company, have been reviewed by another auditor who had expressed an unmodified conclusion on 03 November 2025 and 30 January 2025, respectively.

B S R and Co

**Limited Review Report (Continued)**

**Vijaya Diagnostic Centre Limited**

Our conclusion is not modified in respect of this matter

For **B S R and Co**

*Chartered Accountants*

Firm's Registration No.:128510W

**BALKISHA** Digitally signed by  
BALKISHAN KABRA  
**N KABRA** Date: 2026.02.13  
14:21:06 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

13 February 2026

Membership No.: 221202

UDIN:26221202EGBTUI4344



**VIJAYA  
DIAGNOSTIC  
CENTRE**

Vijaya Diagnostic Centre Limited  
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and year-to-date ended 31 December 2025

		(Rs. in Lakhs except as stated)					
Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited (Refer Note 5)
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	20,521.03	20,156.18	16,898.26	59,482.52	50,814.76	68,139.01
	(b) Other income	510.19	624.86	469.70	1,839.89	1,277.09	1,831.95
	<b>Total income</b>	<b>21,031.22</b>	<b>20,781.04</b>	<b>17,367.96</b>	<b>61,322.41</b>	<b>52,091.85</b>	<b>69,970.96</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	2,402.51	2,431.93	2,085.25	6,975.71	6,259.83	8,476.35
	(b) Employee benefits expense	3,303.65	3,225.93	2,855.48	9,690.29	8,375.00	11,215.28
	(c) Finance costs	859.45	782.72	681.97	2,390.71	1,955.32	2,674.43
	(d) Depreciation and amortisation expense	2,433.89	2,226.70	1,830.46	6,749.60	5,177.60	7,059.74
	(e) Other expenses	6,209.44	6,315.63	5,244.34	18,675.03	15,744.75	21,125.79
	<b>Total expenses</b>	<b>15,208.94</b>	<b>14,982.91</b>	<b>12,697.50</b>	<b>44,481.34</b>	<b>37,512.50</b>	<b>50,551.59</b>
<b>3</b>	<b>Profit before tax and exceptional items [1 - 2]</b>	<b>5,822.28</b>	<b>5,798.13</b>	<b>4,670.46</b>	<b>16,841.07</b>	<b>14,579.35</b>	<b>19,419.37</b>
<b>4</b>	<b>Exceptional items (Refer Note 7)</b>	-	-	-	-	-	102.96
<b>5</b>	<b>Profit before tax [3 - 4]</b>	<b>5,822.28</b>	<b>5,798.13</b>	<b>4,670.46</b>	<b>16,841.07</b>	<b>14,579.35</b>	<b>19,316.41</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	1,165.87	1,263.15	934.41	3,588.65	3,177.90	4,117.77
	(b) Deferred tax, net	338.88	206.68	206.16	747.69	508.57	819.29
	<b>Total tax expense</b>	<b>1,504.75</b>	<b>1,469.83</b>	<b>1,140.57</b>	<b>4,336.34</b>	<b>3,686.47</b>	<b>4,937.06</b>
<b>7</b>	<b>Profit for the period/year [5-6]</b>	<b>4,317.53</b>	<b>4,328.30</b>	<b>3,529.89</b>	<b>12,504.73</b>	<b>10,892.88</b>	<b>14,379.35</b>
<b>8</b>	<b>Other comprehensive income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement of the defined benefit obligations	(3.91)	39.50	(3.72)	26.01	(12.86)	0.53
	(b) Income-tax relating to above item	0.99	(9.94)	0.94	(6.54)	3.24	(0.14)
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>(2.92)</b>	<b>29.56</b>	<b>(2.78)</b>	<b>19.47</b>	<b>(9.62)</b>	<b>0.39</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7+8]</b>	<b>4,314.61</b>	<b>4,357.86</b>	<b>3,527.11</b>	<b>12,524.20</b>	<b>10,883.26</b>	<b>14,379.74</b>
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)</b>	1,027.25	1,027.25	1,026.29	1,027.25	1,026.29	1,026.37
<b>11</b>	<b>Other equity</b>						78,887.88
<b>12</b>	<b>Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 5)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	4.20	4.21	3.43	12.16	10.60	13.99
	- Diluted (in Rs.)	4.19	4.20	3.43	12.14	10.58	13.97

**Notes:**

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).

2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 13 February 2026. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 31 December 2025. An unmodified report has been issued by them thereon.

3. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

4. During the quarter and year-to-date ended 31 December 2025, the Company has issued Nil and 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.

5. The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") of its subsidiary, Medinova Diagnostic Services Limited ("Transferor Company"), with the Company with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder.

The Scheme was sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies.

Accordingly, the Company has accounted for the amalgamation as specified in the Scheme in accordance with the "pooling of interest" method as laid down in Appendix C- 'Business Combinations of Entities Under Common Control' of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year.

In giving effect to the amalgamation:

a. All the assets, liabilities, reserves and surplus as appearing in the transferor company have been transferred and vested in the Company.

b. In consideration for the above Scheme, the Company will issue 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company. The shares of the Company to be issued to the non-controlling shareholders of the transferor company, on the record date, have been presented under 'Other Equity' as 'Shares pending issuance'.

c. The difference between value of share capital of transferor company and existing investment in the transferor company plus the Shares pending issuance as mentioned above has been transferred to 'Amalgamation Reserve' under 'Other Equity'.

Further to the above, the Company, on 8 January 2026, allotted 171,792 equity shares of INR 1 each in exchange for 3,779,420 equity shares held by the non-controlling shareholders of the transferor company. The Company has received in-principle listing approvals from the respective stock exchanges for the listing of 171,792 equity shares and in the process of executing the corporate action with the depositories.

6. The Government of India has consolidated existing labour legislations into four comprehensive labour codes effective November 21, 2025. These codes include Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). However, the final rules under these codes are yet to be notified.

Pending notification, the Group has evaluated the incremental impact of these changes in accordance with the guidance issued by the Institute of Chartered Accountants of India and has estimated and recognized the additional gratuity and leave liability basis the actuarial valuation. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

7. During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.

8. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com.

for and on behalf of the Board of Directors of  
**Vijaya Diagnostic Centre Limited**

SUPRITA  
SURA REDDY

Digitally signed by  
SUPRITA SURA REDDY  
Date: 2026.02.13  
13:58:37 +05'30'

**S Suprita Reddy**  
Managing Director & CEO  
DIN Number: 00263618

Place: Hyderabad  
Date: 13 February 2026

## Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

#### Parent

- a. Vijaya Diagnostic Centre Limited

#### Subsidiaries

- b. VDC Diagnostic (Karnataka) LLP
- c. Medinova Millenium MRI Services LLP
- d. P H Diagnostic Centre Private Limited
- e. Namrata Diagnostic Centre Private Limited (Struck off on 06 April 2024)
- f. Doctorslab Medical Services Private Limited (Struck off on 06 April 2024)
- g. Medinova Diagnostic Services Limited (Amalgamated with the Parent, effective from 1 April 2024)

**Limited Review Report (Continued)**

**Vijaya Diagnostic Centre Limited**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of three subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,245.21 lakhs and Rs. 3,651.86 lakhs, total net profit after tax (before consolidation adjustments) of Rs. (71.23) lakhs and Rs. 36.26 lakhs, total comprehensive income (before consolidation adjustments) of Rs. (71.43) lakhs and Rs. 36.06 lakhs for the quarter ended 31 December 2025 and for the period from 01 April 2025 to 31 December 2025 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

*Chartered Accountants*

Firm's Registration No.:128510W

**BALKISHA** Digitally signed by  
**N KABRA** BALKISHAN KABRA  
Date: 2026.02.13  
14:21:38 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

13 February 2026

Membership No.: 221202

UDIN:26221202QEVKUC7480